natgillin/translations-raw huggingface dataset:
The coupling reaction is conveniently carried out in an inert solvent such as, for example, a halogenated solvent such as methylene chloride, or a dipolar aprotic solvent such as N,N -dimethylformamide, N, N -dimethylacetamide or 1-methyl-2-pyrrolidinone. 
Reakcija spajanja se prikladno provodi u inertnom otapalu poput, na primjer, halogeniranog otapala poput metilen klorida, ili dipolarnog aprotičkog otapala poput N,N-dimetilformamida, N.N-dimetilacetamida ili 1-metil-2- pirolidinona.
is H or F; or a salt or ester thereof. 
R'jeHili F; ili njegova sol ili ester.
A high level of low density lipoprotein (LDL) in the bloodstream has been linked to the formation of coronary lesions which obstruct the flow of blood and can rupture and promote thrombosis. 
Visoka razina lipoproteina niske gustoće (LDL) u krvotoku povezana je s nastankom koronarnih lezija koje usporavaju protok krvi te može doći do njihovog puknuća i razvoja tromboze.
receptor antagonists, having general formula (I) wherein 
antagonisti B2 receptora koji imaju opću formulu (I) [image]
The compound for use according to claim 15 wherein the PI3K is selected from the group consisting of PI3Ka, PI3KB, PI3KY, and PI3Kδ. 
Spoj za upotrebu prema zahtjevu 15 naznačen time da je PI3K izabrano od grupe koja se sastoji od PI3Ko, P13K6, PI3Ky, i PI3K5.
The composition for use according to any one of claims from 1 to 6 wherein said composition is a pharmaceutical composition, is comprised in or consists of a medical device, is comprised in or consists of a dietary supplement or is comprised in a medical food. 
Pripravak za upotrebu u skladu s bilo kojim od patentnih zahtjeva od 1 do 6, naznačen time, da je navedeni pripravak farmaceutski pripravak, sadržan je u ili se sastoji od medicinskog uređaja, sadržan je u ili se sastoji od dodatka prehrani ili je sadržan u medicinskoj hrani.
A method according to any one of claims 13 to 15, the method further comprising the step of; mounting the fixedly positioned magnetic plate (2) and the additional magnet (3) on a rotatable cylinder on a printing machine. 
Postupak sukladno bilo kojem patentnom zahtjevu 13 do 15, naznačen time, da taj postupak dodatno uključuje sljedeći korak: postavljanje fiksirane magnetske ploče (2) i dodatnog magneta (3) na rotirajući valjak na tiskarskom stroju.
A cancer chemotherapeutic agent according to claim 1 or 2, wherein the anti-cancer agent is one or more species selected from the group consisting of a taxane anti-cancer agent, a platinum complex anti-cancer agent, a pemetrexed compound, and fluorouracil. 
10 2. Protutumorsko kemoterapijsko sredstvo u skladu s patentnim zahtjevom 1, naznačeno time, da je protutumorsko sredstvo jedna ili više vrsta odabrana iz skupine koja se sastoji od kompleksa-platine protutumorskog sredstva, 3.
The antibody of claim 1 or claim 2, wherein said antibody comprises an isolated polypeptide comprising a heavy chain variable region sequence of SEQ ID NO:40. 
Antitijelo u skladu sa zahtjevom 1 ili zahtjevom 2, naznačeno time, da navedeno antitijelo sadrži izolirani polipeptid koji sadrži sekvencu teškog lanca varijabilne regije od SEQ ID NO: 40.
The binding protein of claim 1, wherein said ankyrin repeat domain is conjugated at its C-terminus via a peptide bond to a polypeptide linker and a C-terminal Cys residue, wherein the thiol of said C-terminal Cys is further conjugated to said polyethylene glycol moiety, wherein said polyethylene glycol moiety is a maleimide-coupled polyethylene glycol, and wherein said polypeptide linker has a length between 2 and 24 amino acids. 
Vezivni protein sukladno patentnom zahtjevu 1, naznačen time, da je navedena domena ponavljanja ankirina konjugirana na njegovom C-završetku putem peptidne veze s polipeptidnim linkerom i C-terminalnim Cis ostatkom, pri čemu je tiol navedenog C- terminalnog Cis dalje konjugiran s navedenim ostatkom polietilenglikola, pri tome je navedeni polietilenglikolni ostatak polietilenglikol kuplovan s maleimidom i pri tome je polipeptidni linker dužine između 2 i 24 aminokiselina.
To this tank were added cetyl alcohol, stearyl alcohol, 2-octyldodecanol, coconut fatty acid diethanolamide, vaseline album, polysorbate 60, light liquid paraffin, sorbitanmonostearate and benzyl alcohol. 
U ovu posudu dodan je cetilni alkohol, stearilni alkohol, 2-oktildodekanol, dietanolamid masne kiseline kokosa, bijeli vazelin, polisorbat 60, laki tekući parafin, sorbitanmonostearat i benzilni alkohol.
Phosphorous pentachloride (32.8 g, 157.5 mmol, 2.5 eq) was added in portions over 30 minutes to a stirred solution of the reduced tetrabenazine product from Example 1A (20 g, 62.7 mmol) in dichloromethane (200 ml) at 0 °C. After the addition was complete, the reaction mixture was stirred at 0 °C for a further 30 minutes and the solution poured slowly into 2M aqueous sodium carbonate solution containing crushed ice (0 °C). 
Fosfor pentaklorid (32.8 g, 157.5 mmol, 2.5 eq) se dodaje u obrocima tijekom 30 minuta u miješanu otopinu reduciranog tetrabenazin produkta iz Primjera LA (20 g, 62.7 mmol) u diklorometanu (200 ml) at 0 "C. Nakon završetka dodavanja, reakcijska smjesa se miješa na 0 "C tijekom daljnjih 30 minuta i otopina se polagano ulije u 2M vodenu otopinu natrij karbonata koja sadrži smrvljeni led (0 "C).
The nonwoven fabric according to claim 15, wherein the first and second pluralities of the bonded portions are arranged in alternating rows. 
Netkani materijal prema zahtjevu 7, naznačen time da su složene jedinice raspoređene u naizmjeničnim redovima.
a ball nut (55b) screwed to said ball screw shaft and connected to said top mold mounting member; 
kuglasta matica (55b) navijena na tu kuglastu navojnu šipku i spojena za taj dio za namještanje gornjeg kalupa;
Fig. 4 shows a schematic for another variant of the circuit in fig. 2. 
S1. 4 prikazuje shemu za još jednu varijantu kruga sa slike 2.
Rc is, at each occurrence, independently selected from: C3-6 cycloalkyl substituted with 0-2 Rd, C3-6 cycloalkenyl substituted with 0-2 Rd, —(CH2)m-(phenyl substituted with 0-3 Rd), and (a 5- to 6-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NRe, O, and S; wherein said heterocycle is substituted with 0-2 Rd); 
R* je, pri svakom pojavljivanju, nezavisno odabrano od: Cs4 cikloalkil supstituiran sa 0-2 R", C34 cikloalkenil supstituiran sa 0-2 R", (CH>),,-(fenil supstituiran sa 0-3 R"), i (5- do 6-očlani heterociklus koji sadrži ugljikove atome i 1-4 heteroatoma odabrana od N, NR", O, i S; gdje spomenuti heterociklus je supstituiran sa 0-2 R");
In some embodiments, each n is 0 or 1. In some embodiments, n is 0. 
Y? je dušik i R' je odsutan; i svaki n je 0 ili 1.
first and second vertical elongated members fastened to the first, second, third, and fourth horizontal elongated members, the first and fourth horizontal elongated members forming respectively a top and a bottom of the structural truss panel, the first and second vertical elongated members forming respective sides of the structural truss panel, the second and third horizontal elongated members form a double horizontal brace that connects to each of the first and second vertical elongated members, the first, second and third horizontal elongated members forming an integrated truss for attachment to floor and/or ceiling trusses; 
Postupak prema zahtjevu 4, naznačen time da nadalje sadrži: pričvršćivanje prvog rešetkastog nosača poda i/ili stropa na integrirani rešetkasti dio prve konstrukcijske rešetkaste ploče tako da prva rešetka poda i/ili stropa nosi element koji sadrži strop prvog prostora definiranog barem djelomično s prvom strukturnom rešetkastom pločom (20) i pod od drugog prostora definiranog barem djelomično s drugom strukturnom rešetkastom pločom (20); te
A pharmaceutical combination, containing a compound according to any one of claims 1-13, or a pharmaceutically acceptable salt or an isomer thereof, and one or more therapeutic active substances, wherein said therapeutic active substance is selected from angiotensin II receptor antagonist or a pharmaceutically acceptable salt; HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt; calcium-channel blocker (CCB) or a pharmaceutically acceptable salt; dual angiotensin-convertion enzyme/neutral endopeptidase (ACE/NEP) inhibitor or a pharmaceutically acceptable salt; an antidiabetic drug; an antiobesic drug; aldosterone receptor block agent; endothelin receptor block agent; CETP inhibitor; Na-K-ATPase membrane pump inhibitor; B-adrenergic receptor inhibitor or a-adrenergic receptor blocking agent; neutral endopeptidase (NEP) inhibitor and inotropic agent. 
Farmaceutska kombinacija, koja sadrži spoj prema bilo kojem od zahtjeva 1-15, ili njegovu farmaceutski prihvatljivu sol, 1 jednu ili više terapeutski aktivnih tvari, pri čemu je spomenuta terapeutski aktivna tvar odabrana od antagonista angiotenzin II receptora ili farmaceutski prihvatljive soli; inhibitora HMG-Co-A reduktaze ili farmaceutski prihvatljive soli; blokatora kanala kalcija (CCB) ili farmaceutski prihvatljive soli; inhibitora dvostruke angiotenzin-pretvarajuće enzim/neutralne endopeptidaze (ACE/NEP) ili farmaceutski prihvatljive soli; antidijabetičkog lijeka; lijeka protiv gojaznosti; blokirajućeg agensa aldosteron receptora; blokirajućeg agensa endotelin receptora; CETP inhibitora; inhibitora Na-K-ATPaza membranske pumpe; inhibitora f-adrenergičnog receptora ili blokirajućeg agensa a-adrenergičnog receptora; inhibitora neutralne endopeptidaze (NEP) i inotropičnog agensa.
In certain embodiments, Z is tetrazole or CO2Q. 
Tvar u skladu s patentnim zahtjevom 1, pri čemu je Z jednak CO2Q.
Also, the receiver ceases to produce the acoustic signal, when the receiver and transmitter are communicating. 
Isto tako, prijemnik prestane sa zvučnim signalom, kad su prijemnik i odašiljač u vezi.
A compound as claimed in claim 1 having the structure or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, sa strukturom [image], ili njegova farmaceutski prihvatljiva sol ili solvat.
To 2100 ml of methanol was added 60.0 g of nebivolol base at room temperature. 
U 40 g amida (V) dodano je 400 ml toluena.
Electroshock test was applied 60 min following injection and the duration of each seizure was determined. 
Test elektrošokom primijenjen je tijekom 60 minuta nakon injekcije i određeno je trajanje svakog napada.
The method of claim 2, wherein the plastic sheet is less than 400 microns in thickness. 
Postupak proizvodnje oglasne ploče (100) kao što je navedeno u zahtjevu 2, naznačen time da je plastična folija (302) debljine manje od 400 mikrona.
Supplementary therapies include other glucose lowering treatments, such as insulin, an insulin sensitivity enhancer and other drug treatments, a change in diet (low sugar, fats, etc.), weight loss surgery—(reducing stomach volume by gastric bypass, gastrectomy), gastric banding, gastric balloon, gastric sleeve, etc. 
(a) operacija gubitka težine, gastrični bypass, gastrektonomija, želučani balon ili želučani rukav; ili (b) sredstvo za snižavanje glukoze, inzulin, GLP1 analog, bigvanid, sulfonilurea, tiazolidindioni, inhibitor dipeptidil _ peptidaze-4 (DPP-4), formulacija bromokriptina, sekvestrant žučne kiseline, "metformin, tiazolidindioni (TZT), SGLT-2 inhibitor, ili bilo koja njihova kombinacija.
more than 24 hours previous, but no longer than 4 weeks), more distant (e.g. 
više od prethodnih 24 sata, ali ne dulje od 4 tjedna), dalje (na pr.
Per single dose, 50 ug R,R-glycopyrrolate and 500 ug AWD 12-281 are released from a powder inhaler and supplied to the patient's airways. A combination of topical R,R-glycopyrrolate or a physiologically acceptable salt thereof with rolipram or a physiologically acceptable salt thereof for the treatment of bronchial asthma or chronic obstructive pulmonary disease (COPD). 
HR P20120286 T1 PATENTNI ZAHTJEVI Uporaba kombinacije topičkog R,R-glikopirolata ili njegove fiziološki prihvatljive soli s inhibitorima (PDE) 4 fosfodiesteraze odabrane iz skupine koja sadrži rolipram, roflumilast ili njihove fiziološki prihvatljive soli, naznačena time, da je za proizvodnju lijeka za liječenje bronhijalne astme ili kronične opstruktivne bolesti pluća (COPD).
In other embodiments, the pharmaceutical composition may comprise up to 4500 mg of amoxicillin and up to 300 mg rifabutin. 
Kapsula u skladu s patentnim zahtjevom 21, naznačena time što se svakodnevno primjenjuje do 4500 mg amoksicilina i do 300 mg rifabutina.
The composition of claim 8, wherein in the dihydroazole compound of formula (I): is CH2; 
Veterinarski ili agrikulturni sastav prema zahtjevu 8, naznačen time, da u spoju dihidroazola formule (1):
This may include inserting “gaps” in either one or both sequences, to enhance the degree of alignment. 
Ovo može uključivati uvođenje «jazova» u jednu ili obje sekvence kako bi se povećao stupanj sravnjenja.
During this technology the active ingredient is applied onto water-insoluble quartz or glass granules from a solution of methoprolol fumarate or succinate in ethanol-dichloromethane by a layering process. 
Tijekom te tehnologije, aktivan sastojak primjenjuje se na kvare koji je netopljiv u vodi ili na staklene granule iz otopine metoprolol fumarata ili HR P20070322 T3 sukcinata u etanol-diklormetanu postupkom nanošenja sloja.
and wherein the protein carrier is a protein defined in claim 15. A pharmaceutical composition comprising (a) a modified saccharide according to any one of claims 1 to 10 and/or a saccharide-protein conjugate according to claim 15 and/or a molecule according to claim 18 or 19, and (b) a pharmaceutically acceptable carrier, particularly further comprising a saccharide antigen from one or more of serogroups C, W135 and Y of N.meningitidis, the saccharide optionally being an oligosaccharide and optionally being conjugated to a carrier protein, and/or further comprising a vaccine adjuvant such as an aluminium phosphate. 
Farmaceutski pripravak, naznačen time što sadrži (a) modificirani saharid u skladu s bilo kojim od patentnih zahtjeva 1 do 10 i/ili saharidno-proteinski konjugat u skladu s patentnim zahtjevom 15 i/ili molekulu u skladu s patentnim zahtjevom 18 ili 19, i (b) farmaceutski prihvatljivi nosač, koji osobito dodatno sadrži saharidni antigen iz jedne ili više seroskupina C, W'35 i Y iz bakterije N. meningitidis, gdje saharid može biti oligosaharid i može biti konjugiran s proteinskim nosačem, i/ili dodatno sadrži cjepivni adjuvans, poput aluminijevog fosfata.
The peptide according to any one of claims 1 to 4 for use in the treatment of cancer or for use in the manufacture of a vaccine against cancer. 
Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 5, stanica u skladu s patentnim zahtjevom 8 ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 11 za upotrebu u liječenju karcinoma.
The process for the stereoselective preparation according to claim 5, wherein the compound of formula (V), alternatively its enantiomer (V′), reacts 
Postupak stereoselektivne pripreme prema zahtjevu 6, gdje spoj formule (V), alternativno njegov enantiomer (V*), Teagira
In another specific embodiment, the VL CDR1 comprises, consists essentially of or consists of the amino acid sequence set forth in SEQ ID NO:1; the VL CDR2 comprises, consists essentially of or consists of the amino acid sequence set forth in SEQ ID NO:2; the VL CDR3 comprises, consists essentially of or consists of the amino acid sequence set forth in SEQ ID NO:3; the VH CDR1 comprises, consists essentially of or consists of the amino acid sequence set forth in SEQ ID NO:4; the VH CDR2 comprises, consists essentially of or consists of the amino acid sequence set forth in SEQ ID NO:5; and the VH CDR3 comprises, consists essentially of or consists of the amino acid sequence set forth in SEQ ID NO:6. 
Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što VL CDR1 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:1; VL CDR2 sadrži ili ga čim aminokiselinski slijed iznijet u SEQ ID NO:2; VL CDR3 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:3; Vag CDRI sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:4; Vu CDR2 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:5; i Va CDR3 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:6.
Example 12: Preparation of donepezil hydrochloride polymorph I kg of donepezil base were suspended at room temperature (20 -25 °C) in methanol (30 1) and heated to 60-65 °C to get a clear solution. 
Primjer 12: Priprema donepezil hidroklorid polimorfa 4,98 kg donepezilne baze suspendirano je na sobnoj temperaturi (20-25 *C) u metanolu (30 L) i zagrijano na 60-65 "C s ciljem dobivanja bistre otopine.
dissolving the tramadol, or one of the pharmaceutically acceptable salts thereof, in a sufficient quantity of water, 
otapanja tramadola, ili jedne od njegovih farmaceutski prihvatljivih soli, u dovoljnoj količini vode,
The compound for use of claim 1, wherein the disease or disorder is multiple myeloma. The compound for use of claim 1, wherein the disease or disorder is glioblastoma. The compound for use of claim 1, wherein the disease or disorder is lymphoma. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je karcinom jajnika. Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak debelog crijeva.
R7, is H or taken together with R7 forms a C3-C6cycloalkyl ring optionally substituted with R7'a wherein; 
' je H ili zajedno s R7 formira C3-C6cikloalkil prsten po izboru supstituiran s R7'a gdje:
Floor panel according to any of the claims 1 to 6, characterized in that it is formed by coextrusion. 
Podni panel prema patentnom zahtjevu 1 do 6, naznačen time što je element za blokiranje (12) napravljen koekstruzijom.
A pharmaceutical composition according to claim 13 or 14, wherein the transmucosal penetration enhancer is sodium lauryl sulphate. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 13 ili 14, naznačen time, da je sredstvo za poboljšanje transmukozne penetracije natrijev lauril sulfat.
A set of primers consisting of the following pair of primers. 
Komplet početnica, naznačen time što ga čini sljedeći par početnica:
The composition according to claim 15, wherein the amount of calcipotriol or calcipotriol monohydrate is 0.001 or 0.002% w/w of the composition. 
Kompozicija prema zahtjevu 2, pri čemu je analog vitamina D kalcipotriol ili kalcipotriol monohidrat.
A pharmaceutical composition comprising a drug carrier and a double-stranded nucleic acid molecule, wherein the drug carrier comprises a polyethylene glycol molecule-conjugated retinoid molecule, and wherein the double-stranded nucleic acid molecule comprises the structure: 
Farmaceutski pripravak, naznačen time što sadrži: dvolančanu molekulu nukleinske kiseline i nosač lijekova, koji sadrži smjesu retinoida i lipida, gdje dvolančana molekula nukleinske kiseline ima strukturu (A1):
The minimum calorie reduction obtained by substitution of sugar by the functional sugar replacer should be 60 %, when sugar is replaced for 100 %. 
Zamjenom šećera funkcionalnom zamjenom za šećer, kalorijska se vrijednost mora smanjiti na 60 % ako je zamijenjeno 100 % šećera.
The method of claim 2 wherein the pain is neuropathic pain. The method of claim 3 wherein the neuropathic pain is fibromyalgia or peripheral neuropathy. 
Spoj ili farmaceutski prihvatljiva sol tog spoja za primjenu u skladu sa patentnim zahtjevom 13 pri čemu neuropatska bol je fibromijalgija ili periferna neuropatija.
To this, 88 ml of piperidine was slowly added at room temperature and stirred for 30 min. 
Ovome je polagano dodano 88 ml piperidina na sobnoj temperaturi te je miješano tijekom 30 minuta.
The method of claim 1, wherein the notifying comprises causing an interrupt in which shared resources assigned to the second program are released subsequent to termination of the grace period. The method of claim 1, wherein registration is performed via a Diagnose instruction, the Diagnose instruction comprising a register parameter to signal that the second program understands a warning track interruption of the warning track facility. 
Postupak u skladu s patentnim zahtjevom #8, naznačen time što se registriranje provodi preko upute za dijagnosticiranje (Diagnose), gdje se uputa za dijagnosticiranje sastoji u registriranju parametra radi signaliziranja da gostujući operativni sustav razumije prekid upozoravajućeg traga sredstva s upozoravajućim tragom.
the diluted solution is spray-dried or lyophilized. 
(c) razrjeđenu otopinu se suši raspršivanjem ili liofilizira.
Headset apparatus according to any preceding claim wherein the attachment means includes an articulation portion (4, 52, 53, 57) via which said article is connected to the reciprocal connection means to be moveable relative to both the earshell and the reciprocal connection means when the earshell is fitted to the reciprocal connection means in use. 
Slušalice prema bilo kojem od prethodnih zahtjeva, naznačene time, da priključni uređaj obuhvaća zglobno vezani odsječak (4, 52, 53, 57) preko kojega je spomenuti predmet spojen na recipročni spojni uređaj, kako bi bio pomičan u odnosu i na školjku za uho kao i na recipročni spojni uređaj, kada je školjka za uho pričvršćena na recipročni spojni uređaj prilikom uporabe.
The pharmaceutical composition for use according to claim 11, which is an anti-cancer vaccine. 
Farmaceutski sastav za uporabu prema zahtjevu 11, naime kao cjepivo protiv karcinoma.
65-75 mg of HPMC having a nominal viscosity of about 4,000 mPa·s when dissolved about 2% by weight) in water 
65-75 mg HPMC-a (hidroksipropilmetilceluloze) nominalne viskoznosti od oko 4.000 mPa·s kada je otopljen (oko 2% po težini) u vodi
The solvent was evaporated under high vacuum and the residue was chromatographed on a silica gel column (solvent:hexanes-ethyl acetate, 3:2) yielding 5.84 g of 42-O-(tert-butyldimethylsilyl)rapamycin as off-white foam. 
Otapalo je upareno pod visokim vakuumom, a ostatak je pročišćen kromatografijom na koloni silikagela (otapalo: heksani - etil-acetat, 3:2) i daje 5,84 g 42-0-(terc-butildimetilsililjrapamicina kao prljavo bijelu krutinu.
A composition comprising desmopressin for use in the treatment of nocturia or nocturnal polyuria by reducing the number of nocturnal voids and/or by reducing nocturnal urine volume and/or by increasing an initial period of sleep undisturbed by nocturnal voids in a female patient in need thereof, the composition comprising an orodispersible dose of 25 microgram of desmopressin, wherein the dose is measured as the free base of desmopressin, wherein the dose is taken 0.8 to 3 hours prior to the patient's bedtime. 
Pripravak koji sadrži dezmopresin za uporabu u liječenju nokturije ili noćne poliurije za povećanje početnog razdoblja nesmetanog spavanja kod ženskog pacijenta kojem je potreban, naznačen time da pripravak sadrži orodisperzibilnu dozu od 25 mikrograma dezmopresina pri čemu se doza mjeri kao slobodna baza dezmopresina i koja se daje pacijentu prije spavanja.
The compound of claim 1, wherein Z is OR6. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što Z je OR6.
The resultant solution was extracted with EtOAc (3 x 20 ml). 
Rezultirajuća otopina je ekstrahirana sa ELOAc (3 x 20 ml).
As used herein, the terms “re-use” and “recycle” are considered to be synonymous and can be used interchangeably throughout the disclosure. 
Na način na koji se ovdje rabe, pojmovi Â«ponovna uporaba» i «reciklirati» su sinonimi te se mogu rabiti zamjenski kroz cijelo razotkrivanje.
This has disadvantages in that after the use of a substantial number of capsules a wearing off of the fixed sealing means can take place such that the quality of the produced beverage is increasingly deteriorated by water passing the no longer properly efficient sealing. 
Ovo rješenje ima takav nedostatak, da nakon upotrebe znatnog broja čahura može nastupiti trošenje fiksiranog sredstva za brtvljenje, tako da se kvaliteta pripremljenog napitka sve više pogoršava zbog prolaza vode kroz brtvu koja više ne brtvi kako bi trebalo.
The system of claim 3, wherein the at least one light source is a light emitting diode. 
Sustav prema patentnom zahtjevu 2, naznačen time, da barem jedan izvor svjetlosti jest dioda koja emitira svjetlost.